Version 1
: Received: 21 October 2024 / Approved: 22 October 2024 / Online: 24 October 2024 (10:24:09 CEST)
How to cite:
Theiakou, F.; Kastanioti, C.; Zavras, D.; Rekkas, D.; Kontodimopoulos, N. Quantifying the Societal Impact of Delayed Access to Innovative Medicines: A Mathematical Framework for Health Policy Decision-Making. Preprints2024, 2024101687. https://doi.org/10.20944/preprints202410.1687.v1
Theiakou, F.; Kastanioti, C.; Zavras, D.; Rekkas, D.; Kontodimopoulos, N. Quantifying the Societal Impact of Delayed Access to Innovative Medicines: A Mathematical Framework for Health Policy Decision-Making. Preprints 2024, 2024101687. https://doi.org/10.20944/preprints202410.1687.v1
Theiakou, F.; Kastanioti, C.; Zavras, D.; Rekkas, D.; Kontodimopoulos, N. Quantifying the Societal Impact of Delayed Access to Innovative Medicines: A Mathematical Framework for Health Policy Decision-Making. Preprints2024, 2024101687. https://doi.org/10.20944/preprints202410.1687.v1
APA Style
Theiakou, F., Kastanioti, C., Zavras, D., Rekkas, D., & Kontodimopoulos, N. (2024). Quantifying the Societal Impact of Delayed Access to Innovative Medicines: A Mathematical Framework for Health Policy Decision-Making. Preprints. https://doi.org/10.20944/preprints202410.1687.v1
Chicago/Turabian Style
Theiakou, F., Dimitris Rekkas and Nikolaos Kontodimopoulos. 2024 "Quantifying the Societal Impact of Delayed Access to Innovative Medicines: A Mathematical Framework for Health Policy Decision-Making" Preprints. https://doi.org/10.20944/preprints202410.1687.v1
Abstract
This study presents a novel statistical framework for evaluating the social and economic impact of delays in the reimbursement of innovative medicines. With the growing importance of timely access to advanced therapies, particularly in managing chronic diseases, we develop a model that quantifies social loss in terms of life years, productivity, productivity cost and overall well-being. The framework integrates several key factors, including years of life lost, years of potential productive life lost, deaths, delays in reimbursement, and cost of labor productivity losses. By providing a comprehensive assessment of the societal costs associated with delayed access, the model offers valuable insights for policymakers seeking to balance healthcare innovation with sustainability. The results emphasize the need for efficient pharmaceutical policies that reduce delays in access to innovative treatments, promote equity in healthcare, and ensure long-term system viability. This approach has broad implications for improving health outcomes and economic productivity, particularly in publicly funded healthcare systems.
Keywords
pharmaceutical policy; innovative medicines; social loss; reimbursement delays; health economics; quality-adjusted life years (QALYs)
Subject
Public Health and Healthcare, Health Policy and Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
*
